NOW AVAILABLE!

MYCAPSSA® (octreotide) delayed-release oral capsules is the first and only FDA-approved oral somatostatin analog (SSA) for appropriate patients with acromegaly, providing effective and consistent biochemical control, while freeing patients from the burden of injections.1-3

  • MYCAPSSA is powered by patented Transient Permeability Enhancer (TPE®) technology4
  • MYCAPSSA maintained normal IGF-I levels in most patients who switched from injectable SSAs2,3
  • BID oral dosing leads to consistent biochemical control3

With MYCAPSSA, your patients can finally step away from the burden of painful monthly injections.

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Learn More

Introducing TPE Technology

MYCAPSSA offers oral delivery of octreotide, made possible by Transient Permeability Enhancer, TPE, Technology. This method of delivering octreotide orally can help patients overcome the burden and challenges associated with injectable SSA administration, such as pain and injection site reactions.4-6

Watch the full video here to see TPE technology in action.

A Nursing Perspective Webinar

You are invited to a clinical presentation, “Understanding MYCAPSSA and Available Resources: A Nursing Perspective.” This event will be held on September 30, 2020, at 7:30 PM ET and will discuss how to get appropriate patients with acromegaly started on MYCAPSSA, presented by Daphne Adelman, BSN, MBA Clinical Nurse Specialist with Chiasma. This will be followed by a roundtable discussion with a leading endocrinologist and two other nurse key opinion leaders in the field of acromegaly, as well as a live Q&A.

Register now to join us for this special event!

Register Now

By clicking ‘Submit,’ I agree to receive communications from Chiasma, Inc., and I understand that my information will be used in accordance with the Chiasma, Inc. Privacy Policy.

Enrolling Your Patients

Ready to get your patients started on MYCAPSSA?

A simple enrollment form helps start the process so your dedicated Patient Care Specialists from the Chiasma Access and Patient Support Program, also known as “CAPS”, can start working with your office and ensure patient access to MYCAPSSA.

Get Started

Have Questions?

If you’re interested in learning more about MYCAPSSA or have any questions, we’re always here to help. Contact us or schedule a conversation with fellow specialists in the treatment of acromegaly.

Talk to our Team

The Chiasma, Inc. Team is here to help. Request a conversation now!

LEARN MORE

Medical Inquiries

Submit your question to a Chiasma US Medical Information Healthcare Professional to get accurate, unbiased, and balanced evidence-based product information.

Call 1-844-312-2462 or Email us at [email protected]

Speak with Investigators

Schedule a call with an investigator who has experience with MYCAPSSA. Just enter your information to get started.

GET STARTED

Sign up now

Learn more about how MYCAPSSA is changing acromegaly treatment.

   

*Required Field

 

By clicking ‘Submit,’ I agree to receive communications from Chiasma, Inc., and I understand that my information will be used in accordance with the Chiasma, Inc. Privacy Policy.

READ MORE  

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when MYCAPSSA is used with combined oral contraceptives.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

READ MORE  

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when MYCAPSSA is used with combined oral contraceptives.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

REFERENCES

1. Colao A, et al. Nat Rev Dis Primers 2019;5(1):20. 2. MYCAPSSA. Prescribing information. Chiasma, Inc.;2020. 3. Samson SL, et al. J Clin Endocrinol Metab. [published online 16 August 2020]. 4. Melmed S, et al. J Clin Endocrinol Metab. 2015;100(4):1699-1708. 5. Geer EB, et al. Pituitary. 2020. https://doi.org/10.1007/s11102-019-01013-2 6. Strasburger CJ, et al. Eur J Endocrinol. 2016;174(3):355-362. 7. Karsdal MA, et al. Br J Clin Pharmacol. 2015;79(5):720-732. 8. Data on file. Chiasma, Inc.